ClinicalTrials.gg
CompletedNCT05877547Updated Jan 12, 2026

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

A Phase 2 interventional study of Efinopegdutide and Semaglutide in Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic and NAFLD, sponsored by Merck Sharp & Dohme LLC. Completed at 175 sites in 26 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
Largest of 10
381 · median 113
Started
2023
with 1 other
Phase 2
7 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 2, and was the 8th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease
  • Fatty Liver, Nonalcoholic
  • NAFLD
  • Nonalcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of NASH, defined as NAFLD Activity Score (NAS) ≥4 with a score ≥1 point in each component (steatosis, ballooning, and lobular inflammation) AND NASH clinical research network (CRN) fibrosis score of Stage 2 or 3
  • No history of Type 2 diabetes mellitus (T2DM) OR a history of T2DM with an ≤9% that is controlled by diet or stable doses of antihyperglycemic agents (AHAs)
  • Participants in South Korea are eligible between the ages of 19 to 80 years of age (inclusive)

Exclusion criteria

Exclusion Criteria:

  • History of liver disease other than NASH
  • History or evidence of cirrhosis
  • History of pancreatitis
  • History of Type 1 diabetes mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatectomy
  • History of a bariatric surgical procedure ≤5 years before study entry, or a known gastric emptying abnormality
  • Has significant systemic or major illnesses, including recent events (≤6 months before study entry) of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    Efinopegdutide 4mg

    Efinopegdutide administered by subcutaneous (SC) injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks and 4mg for 48 weeks.

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide 7mg

    Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, and 7 mg for 44 weeks.

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide 10mg

    Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for 40 weeks.

    Drug: Efinopegdutide

  • Placebo comparator
    Placebo

    Placebo administered by SC injection once weekly for 52 weeks

    Drug: Placebo

  • Active comparator
    Semaglutide 2.4 mg

    Semaglutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and 2.4 mg for 36 weeks.

    Drug: Semaglutide

Interventions

  • Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg

    Also known as: MK-6024, HM12525A, JNJ-64565111

  • SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg

    Also known as: Wegovy

  • DrugPlacebo

    SC injection of matching placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52

    The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) is used to assess treatment response. The NASH CRN scoring scales are: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution is defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.

    Time frame: Week 52

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An adverse event (AE) is a health problem that happens or worsens during a study.

    Time frame: Up to 60 weeks

  3. Percentage of Participants Discontinuing Study Medication Due to an AE

    An adverse event (AE) is a health problem that happens or worsens during a study.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis At Week 52

    Participants will be assessed using the NASH CRN scoring system evaluated by BICR for ≥1-stage improvement in fibrosis without worsening of steatohepatitis. Fibrosis is scored from stage 0 to 4 where 0 = None, 1=Perisinusoidal OR periportal, 2=Perisinusoidal AND portal/periportal, 3= Bridging fibrosis, 4=Cirrhosis. No worsening of steatohepatitis is defined as no increase in the ballooning, inflammation, or steatosis scores.

    Time frame: Week 52

  2. Change from Baseline in Body Weight At Week 52

    Body weight (kg) will be measured using a standardized, digital scale. The percent change from baseline in body weight after 52 weeks will be reported.

    Time frame: Week 52

07

Study locations

175 sites
  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3
    Chandler, Arizona 85224, United States
  • The Institute for Liver Health II dba Arizona Clinical Trials - Peoria ( Site 3289)
    Peoria, Arizona 85381, United States
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 3218)
    Tucson, Arizona 85712, United States
  • Del Sol Research Management, LLC ( Site 3211)
    Tucson, Arizona 85715, United States
  • Om Research - Apple Valley ( Site 3244)
    Apple Valley, California 92307, United States
  • Om Research LLC ( Site 3245)
    Camarillo, California 93012, United States
  • Velocity Clinical Research, Gardena ( Site 3225)
    Gardena, California 90247, United States
  • Velocity Clinical Research, Huntington Park ( Site 3217)
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, San Diego ( Site 3226)
    La Mesa, California 91942, United States
  • Om Research LLC ( Site 3229)
    Lancaster, California 93534, United States
  • Velocity Clinical Research, Westlake ( Site 3216)
    Los Angeles, California 90057, United States
  • Velocity Clinical Research, Panorama City ( Site 3214)
    Panorama City, California 91402, United States
  • California Liver Research Institute ( Site 3232)
    Pasadena, California 91105, United States
  • Clinical Trials Research ( Site 3230)
    Sacramento, California 95821, United States
  • Excel Medical Clinical Trials ( Site 3246)
    Boca Raton, Florida 33434, United States
  • Synergy Healthcare ( Site 3286)
    Bradenton, Florida 34208, United States
  • Synergy Healthcare LLC ( Site 3290)
    Brandon, Florida 33511, United States
  • Top Medical Research ( Site 3209)
    Cutler Bay, Florida 33189, United States
  • Covenant Metabolic Specialists, LLC ( Site 3231)
    Fort Myers, Florida 33912, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 3241)
    Hallandale, Florida 33009, United States
  • Indago Research & Health Center, Inc ( Site 3207)
    Hialeah, Florida 33012, United States
  • Sweet Hope Research Specialty, Inc-Research ( Site 3200)
    Hialeah, Florida 33016, United States
  • Florida Research Institute ( Site 3243)
    Lakewood Rch, Florida 34211, United States
  • Genoma Research Group ( Site 3242)
    Miami, Florida 33173, United States
  • Floridian Clinical Research, LLC ( Site 3203)
    Miami Lakes, Florida 33016-1518, United States
  • Southeast Clinical Research Center ( Site 3288)
    Dalton, Georgia 30720, United States
  • Eagle Clinical Research ( Site 3233)
    Chicago, Illinois 60621, United States
  • University of Iowa ( Site 3213)
    Iowa City, Iowa 52242, United States
  • Kansas City Research Institute ( Site 3249)
    Kansas City, Missouri 64131, United States
  • The Machuca Foundation ( Site 3234)
    Las Vegas, Nevada 89101, United States
  • Velocity Clinical Research, Syracuse ( Site 3227)
    East Syracuse, New York 13057, United States
  • New York Gastroenterology Associates ( Site 3252)
    New York, New York 10075, United States
  • Velocity Clinical Research, Cincinnati ( Site 3237)
    Cincinnati, Ohio 45242, United States
  • Velocity Clinical Research, Providence ( Site 3222)
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research, Austin ( Site 3235)
    Austin, Texas 78759, United States
  • South Texas Research Institute - Brownsville ( Site 3285)
    Brownsville, Texas 78520, United States
  • Velocity Clinical Research, Dallas ( Site 3220)
    Dallas, Texas 75230, United States
  • Houston Research Institute ( Site 3262)
    Houston, Texas 77079, United States
  • American Research Corporation ( Site 3202)
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research ( Site 3284)
    San Antonio, Texas 78229, United States
  • Velocity Clinical Research, Salt Lake City ( Site 3223)
    West Jordan, Utah 84088, United States
  • Gastroenterology Consultants of Southwest Virginia ( Site 3282)
    Roanoke, Virginia 24014, United States
  • Medizinische Universität Graz-Department of Internal Medicine ( Site 0302)
    Graz, Styria 8036, Austria
  • Antwerp University Hospital-Gastr-enterologie/hepatologie ( Site 3300)
    Edegem, Antwerpen 2650, Belgium
  • AZ Maria Middelares-Digestief Centrum ( Site 3301)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven-Hepatology ( Site 3302)
    Leuven, Vlaams-Brabant 3001, Belgium
  • Heritage Medical Research Clinic ( Site 0403)
    Calgary, Alberta T2N 4Z6, Canada
  • Vancouver General Hospital-Gastroenterology ( Site 0408)
    Vancouver, British Columbia V5Z 1M9, Canada
  • Toronto General Hospital ( Site 0402)
    Toronto, Ontario M5G 2C4, Canada
  • McGill University Health Centre ( Site 0400)
    Montreal, Quebec H4A 3J1, Canada
  • Diex Recherche Quebec Inc. ( Site 0409)
    Québec, Quebec G1V 4T3, Canada
  • Enroll SpA ( Site 0501)
    Providencia, Region M. de Santiago 7500587, Chile
  • CECIM ( Site 0500)
    Santiago, Region M. de Santiago 8320000, Chile
  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0502)
    Santiago, Region M. de Santiago 8330032, Chile
  • Beijing Youan Hospital ( Site 0602)
    Beijing, Beijing Municipality 100069, China
  • Beijing Tsinghua Changgung Hospital ( Site 0606)
    Beijing, Beijing Municipality 102218, China
  • Chongqing University Three Gorges Hospital ( Site 0607)
    Wanzhou, Chongqing Municipality 404000, China
  • The First Affiliated Hospital, Sun Yat-sen University ( Site 0603)
    Guangzhou, Guangdong 510080, China
  • Southern Medical University Nanfang Hospital ( Site 0601)
    Guangzhou, Guangdong 510515, China
  • No. 2 Hospital of Nanjing ( Site 0605)
    Nanjing, Jiangsu 210037, China
  • West China Hospital, Sichuan University ( Site 0611)
    Chengdu, Sichuan 610041, China
  • Tianjin Second People's Hospital ( Site 0604)
    Tianjin, Tianjin Municipality 300192, China
  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0609)
    Wenzhou, Zhejiang 325000, China
  • Fundación Centro de Investigación Clínica CIC ( Site 0704)
    Medellín, Antioquia 050021, Colombia
  • Sociedad De Oncología y Hematología Del Cesar SAS ( Site 0708)
    Valledupar, Cesar Department 200001, Colombia
  • Fundacion Santa Fe de Bogota ( Site 0701)
    Bogotá, Cundinamarca 110111, Colombia
  • Solano & Terront Servicios Medicos - UNIENDO ( Site 0705)
    Bogotá, Cundinamarca 110221, Colombia
  • Oncomédica S.A.S ( Site 0702)
    Montería, Departamento de Córdoba 230002, Colombia
  • Fundación Valle del Lili ( Site 0700)
    Cali, Valle del Cauca Department 760026, Colombia
  • KlinMed ( Site 0801)
    Prague, Praha 2 120 00, Czechia
  • Krajská nemocnice Liberec ( Site 0800)
    Liberec, 460 63, Czechia
  • Vseobecna fakultni nemocnice v Praze ( Site 0802)
    Prague, 128 08, Czechia
  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Pôle de Référence Hépato Gastro-entérol
    Nice, Alpes-Maritimes 06202, France
  • CHU Bordeaux Haut-Leveque-Service d'Hépato-gastroentérologie ( Site 0904)
    Pessac, Aquitaine 33600, France
  • Hôpital de la Croix Rousse-Centre de Recherche Clinique ( Site 0911)
    Lyon, Auvergne-Rhône-Alpes 69004, France
  • centre hospitalier lyon sud-Endocrinologie, Diabète et Nutrition ( Site 0906)
    Pierre-Bénite, Auvergne-Rhône-Alpes 69494 Cédex, France
  • CHU Charles Nicolle ( Site 0910)
    Rouen, Haute-Normandie 76000, France
  • Hôpital Beaujon-Hépatologie ( Site 0908)
    Clichy, Hauts-de-Seine 92110, France
  • Centre Hospitalier Universitaire d'Angers-Hepato Gastroenterology ( Site 0900)
    Angers, Maine-et-Loire 49933, France
  • Centre Hospitalier Universitaire Estaing ( Site 0913)
    Clermont-Ferrand, Puy-de-Dome 63100, France
  • Hôpital Saint Antoine ( Site 0914)
    Paris, 75571, France
  • Hopitaux Universitaires Paris Centre-Hopital Cochin-Service HEPATOLOGIE- Recherche Clinique ( Site 0
    Paris, 75679, France
  • Prince of Wales Hospital ( Site 1000)
    Shatin, Hong Kong
  • SYNEXUS Magyarország Kft. Eü. ( Site 1110)
    Budapest, 1036, Hungary
  • Dél-Pesti Centrumkórház-Hepatologiai Szakrendekő ( Site 1102)
    Budapest, 1097, Hungary
  • Barzilai Medical Center ( Site 1306)
    Ashkelon, 7830604, Israel
  • Rambam Health Care Campus ( Site 1304)
    Haifa, 3109601, Israel
  • Carmel Hospital ( Site 1305)
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center-Liver Unit ( Site 1302)
    Jerusalem, 9778419, Israel
  • Rabin Medical Center ( Site 1301)
    Petah Tikva, 4941 492, Israel
  • Sheba Medical Center ( Site 1300)
    Ramat Gan, 5265601, Israel
  • Maccabi Health Services - Ramat Hasharon ( Site 1303)
    Ramat HaSharon, 4731001, Israel
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Dipartimento di Medicina Interna e Gas
    Rome, Lazio 00168, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 1403)
    Milan, Lombardy 20122, Italy
  • Humanitas-Medicina interna ed Epatologia ( Site 1400)
    Rozzano, Lombardy 20089, Italy
  • A.O.U. Policlinico Paolo Giaccone-Dep. Of Internal Medicine and Specialistic ( Site 1402)
    Palermo, Sicily 90127, Italy
  • Azienda Ospedaliero-Universitaria Città della Salute e della-S.C. Gastroenterologia U. ( Site 1401)
    Torino, 10126, Italy
  • Ehime University Hospital ( Site 1509)
    Tōon, Ehime 7910295, Japan
  • Kurume University Hospital ( Site 1504)
    Kurume, Fukuoka 830-0011, Japan
  • Ogaki Municipal Hospital ( Site 1511)
    Ōgaki, Gifu 503-0864, Japan

Showing the first 100 of 175 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Dec 2025, 30 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 30 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 26, 2023
StartActual
Jun 23, 2023
Primary completionActual
Dec 29, 2025
CompletionActual
Dec 29, 2025
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05877547
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Jun 23, 2023
Primary completion
Dec 29, 2025
Completion
Dec 29, 2025
Last update
Jan 12, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion